Basel Medical Group Ltd (BMGL) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Basel Medical Group Ltd (BMGL:NASDAQ), powered by AI.

Current Price
$0.59
Sector
Healthcare
What is the Basel Medical Group Ltd stock price forecast?

Basel Medical Group Ltd is currently trading at $0.59. View real-time AI analysis on Alpha Lenz.

What is Basel Medical Group Ltd insider trading activity?

View the latest insider trading data for Basel Medical Group Ltd on Alpha Lenz.

What is Basel Medical Group Ltd's P/E ratio?

View Basel Medical Group Ltd's valuation metrics on Alpha Lenz.

Basel Medical Group Ltd

$0.59
NASDAQBMGL
Ask about Basel Medical Group Ltd's future dividend policy...
Alpha Chat Insight

Basel Medical Group Ltd's ROE is -194.6%. Explore profitability and growth together.

Ask for details

Company Overview

Basel Medical Group Ltd is a healthcare services provider headquartered in Singapore, operating primarily through its specialized medical clinics. The company focuses on general and subspecialized orthopedic, trauma, sports medicine, and neurosurgical services, offering procedures such as knee and hip replacements, spine surgery, minimally invasive techniques, and comprehensive consultations and diagnostics. Basel Medical Group has established itself within Singapore's healthcare sector and recently expanded its presence through the acquisition of Bethesda Medical Pte. Ltd., a move that broadened its service portfolio to include diagnostic imaging, outpatient care, occupational health, women's health, mental health, and seafarer health services. This integration aims to streamline referrals and enhance patient outcomes throughout the region. Founded in 2001 and incorporated as a public entity in 2023, Basel Medical Group plays an important role in meeting the growing healthcare needs of Southeast Asia by combining specialized care with broader outpatient and preventive services, positioning itself as a dynamic participant in the regional medical landscape.

CEODr. Yen Feng Chhoa M.D.
SectorHealthcare
IndustryMedical Care Facilities
Employees32

Company Statistics

(FY 2025)

Profile

Market CapN/A
Revenue$8.92M
Shares Out0.00
Employees32

Margins

Gross77.68%
EBITDA0.22%
Operating-19.28%
Pre-Tax-110.47%
Net-106.79%

Valuation

P/EN/A
P/BN/A
EV/SalesN/A
EV/EBITDAN/A
P/FCFN/A

Growth (CAGR)

Rev 3Yr3.06%
Rev 5YrN/A
Op Inc 3YrN/A
Op Inc 5YrN/A
Net Inc 3YrN/A
Net Inc 5YrN/A

Returns

ROA-72.90%
ROE-194.60%
ROIC-74.19%

Financial Health

Cash & Cash Equivalents$2.35M
Net Debt$7.10M
Debt/Equity246.48%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Basel Medical Group Ltd (Healthcare) Stock Forecast & Analysis $0.59 | Alpha Lenz